Afirma GRID is a research-use-only resource for analysis of molecular characteristics that may ultimately help improve the understanding of how to manage patients with thyroid nodules and thyroid cancer.

Every Afirma Genomic Sequencing Classifier (GSC) test performed includes whole-transcriptome-derived analysis covering over 21,000 genes and over 98% of the reference sequence exome.23 This data fuels Afirma GRID and can be made available upon request for use on a research-use-only basis for thyroid nodules that are deemed suspicious for cancer by the Afirma GSC or are reported as Bethesda V or VI by cytopathology.

Learn more about Afirma’s whole transcriptome approach here:

We hope that the availability of Afirma GRID will help boost thyroid nodule and cancer research, generate genomic discoveries, identify new molecular markers that may impact patient care, and accelerate clinical trials.

Examples of research conducted in collaboration with Veracyte can be found here:

Afirma GRID
Watch Dr. Joshua Klopper, Veracyte's Medical Director for Endocrinology, explain the Afirma GRID report